AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
90.16
-0.69 (-0.76%)
Dec 4, 2025, 11:21 AM EST - Market open
AstraZeneca Employees
AstraZeneca had 92,900 employees as of December 31, 2024. The number of employees increased by 3,000 or 3.34% compared to the previous year.
Employees
92,900
Change (1Y)
3,000
Growth (1Y)
3.34%
Revenue / Employee
$625,694
Profits / Employee
$101,173
Market Cap
283.29B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
| Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
| Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
| Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
| Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
| Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
| Dec 31, 2013 | 51,500 | -200 | -0.39% |
| Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
| Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
| Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
| Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
| Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
| Dec 31, 2007 | 67,400 | 600 | 0.90% |
| Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
| Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
| Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
| Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
| Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AZN News
- 4 hours ago - AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH - Business Wire
- 2 days ago - Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension - Business Wire
- 7 days ago - Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies - CNBC
- 9 days ago - AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows - Benzinga
- 10 days ago - Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology - PRNewsWire
- 12 days ago - Why AstraZeneca Stock Bumped Higher Today - The Motley Fool
- 12 days ago - AstraZeneca to invest $2 billion as part of US manufacturing push - Reuters
- 12 days ago - AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth - Business Wire